Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.

Pittman JE, Noah H, Calloway HE, Davis SD, Leigh MW, Drumm M, Sagel SD, Accurso FJ, Knowles MR, Sontag MK.

PLoS One. 2017 May 15;12(5):e0177215. doi: 10.1371/journal.pone.0177215. eCollection 2017.

2.

Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa.

Pages-Monteiro L, Marti R, Commun C, Alliot N, Bardel C, Meugnier H, Perouse-de-Montclos M, Reix P, Durieu I, Durupt S, Vandenesch F, Freney J, Cournoyer B, Doleans-Jordheim A.

PLoS One. 2017 Mar 10;12(3):e0173022. doi: 10.1371/journal.pone.0173022. eCollection 2017.

3.

Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.

Junge S, Görlich D, den Reijer M, Wiedemann B, Tümmler B, Ellemunter H, Dübbers A, Küster P, Ballmann M, Koerner-Rettberg C, Große-Onnebrink J, Heuer E, Sextro W, Mainz JG, Hammermann J, Riethmüller J, Graepler-Mainka U, Staab D, Wollschläger B, Szczepanski R, Schuster A, Tegtmeyer FK, Sutharsan S, Wald A, Nofer JR, van Wamel W, Becker K, Peters G, Kahl BC.

PLoS One. 2016 Nov 18;11(11):e0166220. doi: 10.1371/journal.pone.0166220. eCollection 2016.

4.

Update on host-pathogen interactions in cystic fibrosis lung disease.

Hector A, Frey N, Hartl D.

Mol Cell Pediatr. 2016 Dec;3(1):12. doi: 10.1186/s40348-016-0039-5. Epub 2016 Feb 23.

5.

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Qvist T, Taylor-Robinson D, Waldmann E, Olesen HV, Hansen CR, Mathiesen IH, Høiby N, Katzenstein TL, Smyth RL, Diggle PJ, Pressler T.

J Cyst Fibros. 2016 May;15(3):380-5. doi: 10.1016/j.jcf.2015.09.007. Epub 2015 Oct 9.

6.

Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients.

Ormerod KL, George NM, Fraser JA, Wainwright C, Hugenholtz P.

PeerJ. 2015 Sep 15;3:e1223. doi: 10.7717/peerj.1223. eCollection 2015.

7.

Children and young adults with CF in the USA have better lung function compared with the UK.

Goss CH, MacNeill SJ, Quinton HB, Marshall BC, Elbert A, Knapp EA, Petren K, Gunn E, Osmond J, Bilton D.

Thorax. 2015 Mar;70(3):229-36. doi: 10.1136/thoraxjnl-2014-205718. Epub 2014 Sep 25.

8.

Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.

Sriramulu D.

Microbiol Insights. 2013 Apr 14;6:29-36. doi: 10.4137/MBI.S10792. eCollection 2013. Review.

9.

Evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of nonfermenting gram-negative bacilli isolated from cultures from cystic fibrosis patients.

Marko DC, Saffert RT, Cunningham SA, Hyman J, Walsh J, Arbefeville S, Howard W, Pruessner J, Safwat N, Cockerill FR, Bossler AD, Patel R, Richter SS.

J Clin Microbiol. 2012 Jun;50(6):2034-9. doi: 10.1128/JCM.00330-12. Epub 2012 Apr 11.

10.

Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.

Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, Regelmann W; Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis..

J Cyst Fibros. 2012 Jul;11(4):293-9. doi: 10.1016/j.jcf.2012.02.005. Epub 2012 Mar 23.

11.

Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Brooke JS.

Clin Microbiol Rev. 2012 Jan;25(1):2-41. doi: 10.1128/CMR.00019-11. Review.

12.

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies.

Sanders DB, Lai HJ, Rock MJ, Farrell PM.

J Cyst Fibros. 2012 Mar;11(2):150-3. doi: 10.1016/j.jcf.2011.10.002. Epub 2011 Nov 21.

13.

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early Pseudomonas Infection Control (EPIC) Investigators..

Arch Pediatr Adolesc Med. 2011 Sep;165(9):847-56. doi: 10.1001/archpediatrics.2011.136.

14.

Clinical significance of microbial infection and adaptation in cystic fibrosis.

Hauser AR, Jain M, Bar-Meir M, McColley SA.

Clin Microbiol Rev. 2011 Jan;24(1):29-70. doi: 10.1128/CMR.00036-10. Review.

15.

Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Pompilio A, Crocetta V, Confalone P, Nicoletti M, Petrucca A, Guarnieri S, Fiscarelli E, Savini V, Piccolomini R, Di Bonaventura G.

BMC Microbiol. 2010 Apr 7;10:102. doi: 10.1186/1471-2180-10-102.

16.

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ.

J Cyst Fibros. 2010 Jan;9(1):1-16. doi: 10.1016/j.jcf.2009.09.003. Epub 2009 Oct 14. Review.

17.

Recurrent hemoptysis with Penicillium marneffei and Stenotrophomonas maltophilia in Job's syndrome.

Ma BH, Ng CS, Lam R, Wan S, Wan IY, Lee TW, Yim AP.

Can Respir J. 2009 Jul-Aug;16(4):e50-2.

18.

Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.

Coutinho HD, Falcão-Silva VS, Gonçalves GF.

Int Arch Med. 2008 Nov 7;1(1):24. doi: 10.1186/1755-7682-1-24.

19.

Identification and management of unusual pathogens in cystic fibrosis.

Elborn JS.

J R Soc Med. 2008 Jul;101 Suppl 1:S2-5. doi: 10.1258/jrsm.2008.s18002. No abstract available.

20.

The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants.

Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, Saunders D, Arrowsmith C, Carver T, Peters N, Adlem E, Kerhornou A, Lord A, Murphy L, Seeger K, Squares R, Rutter S, Quail MA, Rajandream MA, Harris D, Churcher C, Bentley SD, Parkhill J, Thomson NR, Avison MB.

Genome Biol. 2008 Apr 17;9(4):R74. doi: 10.1186/gb-2008-9-4-r74.

Supplemental Content

Support Center